Table 1 Patients’ Characteristics
Overall (N = 828) | Genotype-A (N = 255) | Genotype-D (N = 573) | P-valued | |
|---|---|---|---|---|
General | ||||
Median Age (IQR), years | 45 (38–59) | 45 (33–56) | 49 (40–59) | 0.001 |
Male, N(%)a | 584 (70.5) | 183 (74.4) | 401 (73.6) | 0.810 |
CHB-related data | ||||
Median HBV-DNA, log IU/ml (IQR) | 4.4 (3.2–6.4) | 4.7(3.3–6.9) | 4.4 (3.2–6.3) | 0.079 |
HBeAg positive, N(%)b | 183 (44.1) | 71 (59.7) | 112 (38) | < 0.001 |
Median ALT, IU/L (IQR) | 46.5 (32–78) | 46 (30–80) | 48 (32–78) | 0.473 |
Geographical origin, N(%) | ||||
Western Europe | 142 (17.1) | 67 (26.3) | 75 (13.1) | < 0.001 |
Northern Europe | 26 (3.1) | 10 (3.9) | 16 (2.8) | 0.519 |
Eastern Europe | 131 (15.8) | 99 (38.8) | 32 (5.6) | < 0.001 |
Southern Europe | 529 (63.9) | 79 (31) | 450 (78.5) | < 0.001 |
Anti-HBV drug history, N(%)c | ||||
Monotherapy | ||||
LAM | 406 (62.5) | 157 (66.8) | 249 (60) | 0.085 |
ADV | 32 (4.9) | 10 (4.3) | 22 (5.3) | 0.554 |
ETV | 31 (4.8) | 7 (3) | 24 (5.8) | 0.107 |
TDF | 5 (0.8) | 2 (0.9) | 3 (0.7) | 0.857 |
LdT | 3 (0.5) | 1 (0.4) | 2 (0.5) | 1.000 |
Dual exposure | ||||
LAM + ADV | 115 (17.7) | 27 (11.5) | 88 (21.2) | 0.002 |
LAM + TDF | 21 (3.2) | 14 (6) | 7 (1.7) | 0.003 |
LAM + ETV | 17 (2.6) | 10 (4.3) | 7 (1.7) | 0.045 |
ADV + ETV | 4 (0.6) | 3 (1.3) | 1 (0.2) | 0.137 |
ETV + TDF | 3 (0.5) | 3 (1.3) | 0 (0) | 0.047 |
ADV + ETV | 1 (0.2) | 0 (0) | 1 (0.2) | 1.000 |
Triple exposure | ||||
LAM + ADV + ETV | 5 (0.8) | 1 (0.4) | 4 (1) | 0.450 |
LAM + ADV + TDF | 7 (1.1) | 0 (0) | 7 (1.7) | 0.045 |